

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/A1DEB2CB902EN.html>

Date: October 2018

Pages: 35

Price: US\$ 3,500.00 (Single User License)

ID: A1DEB2CB902EN

Abstracts

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

SUMMARY

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Aurora Kinase C is a member of the Aurora subfamily of serine/threonine protein kinases. Aurora Kinase C is a chromosomal passenger protein that forms complexes with Aurora-B and inner centromere proteins and plays an important role in organizing microtubules in relation to centrosome function during mitosis. It is over expressed in several cancer cell lines and involved in oncogenic signal transduction.

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Solid Tumor, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Metastatic Breast Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL) and Prostate Cancer.

The latest report Aurora Kinase C - Pipeline Review, H2 2018, outlays comprehensive information on the Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

The report reviews Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Overview

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Companies Involved in Therapeutics Development

AbbVie Inc

Amgen Inc

Cielo Therapeutics Inc

Sanofi

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Drug Profiles

AMG-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-137690 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

danusertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMI-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-156497 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Dormant Products

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Amgen Inc, H2 2018
Pipeline by Cielo Therapeutics Inc, H2 2018
Pipeline by Sanofi, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

COMPANIES MENTIONED

AbbVie Inc

Amgen Inc

Cielo Therapeutics Inc

Sanofi

I would like to order

Product name: Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/A1DEB2CB902EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A1DEB2CB902EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970